Title: The Link Between Gross Profitability And Pharmaceutical R&D Spending
Abstract: Trends Health AffairsVol. 20, No. 5: The Value Of Innovation TRENDSThe Link Between Gross Profitability And Pharmaceutical R&D SpendingF.M. SchererPUBLISHED:September/October 2001No Accesshttps://doi.org/10.1377/hlthaff.20.5.216AboutSectionsView articleView Full TextView PDFPermissions ShareShare onFacebookTwitterLinked InRedditEmail ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions View articleTOPICSPrescription drug costsCosts and spendingPharmaceutical industryPharmaceuticalsResearch and developmentMarketsEthicsCost growthPrescription drugsPharmaceutical companies Loading Comments... Please enable JavaScript to view the comments powered by Disqus. DetailsExhibitsReferencesRelated Article MetricsCitations: Crossref 121 History Published online 1 September 2001 InformationCopyright 2001 by Project HOPE - The People-to-People Health Foundation, Inc.PDF downloadCited byImpact of Pharmaceutical R&D Activity on Financial Flexibility and Bargaining Power8 November 2022 | Economies, Vol. 10, No. 11A Multi-layered Illustration of Exemplary Business Ethics Practices with Voices of the Engineers in the Health Products Industry24 September 2022 | Journal of Business Ethics, Vol. 175Pharmaceutical markets in Japan and the United States9 August 2022 | International Journal of Economic Policy Studies, Vol. 16, No. 2Endogeneity in pharmaceutical knowledge generation: An instrument‐free copula approach for Poisson frontier models27 June 2022 | Journal of Economics & Management Strategy, Vol. 82Innovation and misconduct in the pharmaceutical industryJournal of Business Research, Vol. 144What Determines Profitability in the Indian Automobile Industry?23 December 2021 | The Indian Economic Journal, Vol. 70, No. 1Industrial and Corporate Change, Vol. 31, No. 4Idea Engines: A Unified Theory of Innovation and Obsolescence From Markets and Genetic Evolution to ScienceSSRN Electronic Journal, Vol. 1Mergers and Acquisitions of Research-Based Biopharmaceutical Companies and Their Effects on Productivity and Share PerformanceSSRN Electronic Journal, Vol. 28The Effect of Financial Risk Taking on Profitability in the Pharmaceutical Industry14 October 2021 | Economies, Vol. 9, No. 4Determinants of biopharmaceutical R&D expenditures in China: the impact of spatiotemporal context23 June 2021 | Scientometrics, Vol. 126, No. 8Revisiting the Relationship Between Price Regulation and Pharmaceutical R&D Investment15 July 2020 | Applied Health Economics and Health Policy, Vol. 19, No. 2Spatial Dynamics between Firm Sales and Environmental Responsibility: The Mediating Role of Corporate Innovation4 February 2021 | Sustainability, Vol. 13, No. 4Earnings Component Volatilities: Capital Versus R&D Expenditures10 January 2021 | Production and Operations Management, Vol. 114Innovation efficiency in European high-tech industries: Evidence from a Bayesian stochastic frontier approachResearch Policy, Vol. 49, No. 8Non-Parametric Analysis of Efficiency: An Application to the Pharmaceutical Industry7 September 2020 | Mathematics, Vol. 8, No. 9U.S. Pharmaceutical Markets: Expenditures, Health Insurance, New Products and Generic Prescribing from 1960 to 201624 September 2019 | International Journal of the Economics of Business, Vol. 27, No. 1Manufacturing, Supply and Pricing of Pharmaceuticals: Lessons from Biologically-Derived ProductsSSRN Electronic Journal, Vol. 339Analysis of Health Technology Assessments of Orphan Drugs in Ireland from 2012 to 20179 May 2019 | PharmacoEconomics - Open, Vol. 3, No. 4R&D tax incentive scheme and in-house R&D expenditure: evidences from Indian firmsJournal of Advances in Management Research, Vol. 17, No. 3Health Returns to Pharmaceutical Innovation in the Market for Oral Chemotherapy in Response to Insurance Coverage ExpansionAmerican Journal of Health Economics, Vol. 5, No. 3How financial systems and firm strategy impact the choice of innovation fundingEuropean Journal of Innovation Management, Vol. 23, No. 2Firm growth and R&D investment: SVAR evidence from the world’s top R&D investors2 May 2018 | Industry and Innovation, Vol. 26, No. 5One lab, two firms, many possibilities: On R&D outsourcing in the biopharmaceutical industryJournal of Health Economics, Vol. 65M&A effects on innovation and profitability in large European firmsManagement Decision, Vol. 57, No. 1The price of innovation - the role of drug pricing in financing pharmaceutical innovation. A conceptual framework20 March 2019 | Journal of Market Access & Health Policy, Vol. 7, No. 1Measuring the Efficiency of U.S. Pharmaceutical Companies Based on Open Innovation Types8 August 2018 | Journal of Open Innovation: Technology, Market, and Complexity, Vol. 4, No. 3Impact of the excise tax on firm R&D and performance in the medical device industry: Evidence from the Affordable Care ActResearch Policy, Vol. 47, No. 5Economics of the Pharmaceutical IndustryJournal of Economic Literature, Vol. 56, No. 2R&D Success in Pharmaceutical Markets: A Duration Model Approach15 May 2018Policy to encourage the development of antimicrobials17 April 2018 | International Journal of Health Governance, Vol. 23, No. 2Firm level R&D intensity: evidence from Indian drugs and pharmaceutical industry17 October 2016 | Review of Managerial Science, Vol. 12, No. 1Excess Prices for Drugs in Medicare: Diagnosis and PrescriptionSSRN Electronic JournalFind and Replace: R&D Investment Following the Erosion of Existing ProductsSSRN Electronic JournalAsymmetric Growth and Institutions in an Interdependent WorldJournal of Political Economy, Vol. 125, No. 5Firm level profitability determinants in Indian drugs and pharmaceutical industryInternational Journal of Pharmaceutical and Healthcare Marketing, Vol. 11, No. 3RISKS TO THE RETURNS TO MEDICAL INNOVATION: THE CASE OF MYRIAD GENETICS29 June 2016 | Contemporary Economic Policy, Vol. 35, No. 2One Lab, Two Firms, Many Possibilities: On R&D Outsourcing in the Biopharmaceutical IndustrySSRN Electronic JournalRegulation and welfare: evidence from paragraph IV generic entry in the pharmaceutical industry11 November 2016 | The RAND Journal of Economics, Vol. 47, No. 4A retroductive systems-based methodology for socio-technical transitions researchTechnological Forecasting and Social Change, Vol. 108Structure and Dynamics of the Pharmaceutical Industry12 May 2016Bibliography18 September 2015What Do You Have to Say About That? Performance Events and Narratives' Positive and Negative Emotional Content6 December 2013 | Entrepreneurship Theory and Practice, Vol. 39, No. 4Offshoring and Home Country R&D28 October 2014 | The World Economy, Vol. 38, No. 4Are Settlements in Patent Litigation Collusive? Evidence from Paragraph IV ChallengesSSRN Electronic JournalPharmaceutical regulation in Europe and its impact on corporate R&D3 October 2014 | Health Economics Review, Vol. 4, No. 1Pay-for-Delay Agreements in the Pharmaceutical Sector: Towards a Coherent EU Approach?`20 January 2017 | European Journal of Risk Regulation, Vol. 5, No. 1Pharmaceutical economicsECONOMIA E POLITICA INDUSTRIALE, No. 1Two Paradoxes in the Theory of Capital Investment and Competition6 February 2014 | International Journal of the Economics of Business, Vol. 21, No. 1Knowing when to leap: Transitioning between exploitative and explorative R&D7 May 2013 | Strategic Management Journal, Vol. 35, No. 1R&D Investments, Profitability and Regulation of the Pharmaceutical IndustrySSRN Electronic JournalSystematic Review of Drug Administration Costs and Implications for Biopharmaceutical Manufacturing12 July 2013 | Applied Health Economics and Health Policy, Vol. 11, No. 5R&D EXPENDITURE VOLATILITY AND FIRM PERFORMANCE: ORGANIZATIONAL AND ENVIRONMENTAL CONTEXTS19 September 2013 | International Journal of Innovation and Technology Management, Vol. 10, No. 04Analyses of Direct and Indirect Impacts of a Positive List System on Pharmaceutical R&D InvestmentsClinical Therapeutics, Vol. 35, No. 7The Determinants of Cost-Effectiveness Potential: An Historical Perspective on Lipid-Lowering Therapies10 April 2013 | PharmacoEconomics, Vol. 31, No. 5Structural changes in the German pharmaceutical market: Price setting mechanisms based on the early benefit evaluationHealth Policy, Vol. 109, No. 3EXAMINING THE LINK BETWEEN CASH FLOW, MARKET VALUE, AND RESEARCH AND DEVELOPMENT INVESTMENT SPENDING IN THE MEDICAL DEVICE INDUSTRY2 January 2012 | Health Economics, Vol. 22, No. 2Market size and innovation: Effects of Medicare Part D on pharmaceutical research and developmentJournal of Public Economics, Vol. 97Measuring the Patient Health, Societal and Economic Benefits of US Pediatric Therapeutics Legislation18 December 2012 | Pediatric Drugs, Vol. 14, No. 5BENEFITS OF PHARMACEUTICAL INNOVATION: THE CASE OF SIMVASTATIN IN CANADA19 September 2012 | International Journal of Technology Assessment in Health Care, Vol. 28, No. 4Advance Market Commitments for R&D in Diseases That Disproportionately Affect Low-Income Countries22 July 2012 | The Journal of World Intellectual Property, Vol. 15, No. 4Antihypertensive Drugs: A Perspective on Pharmaceutical Price Erosion and Its Impact on Cost-EffectivenessValue in Health, Vol. 15, No. 2Contribución de Estados Unidos, Europa y Japón al descubrimiento de nuevos fármacos: 1982–2003The Impact of Mergers and Acquisitions in Research-Based Pharmaceutical Companies on ProductivitySSRN Electronic JournalEvergreening: a common practice to protect new drugs13 October 2011 | Nature Biotechnology, Vol. 29, No. 10The Evolution of the Pharmaceutical Industry Over the Past 50 Years: A Personal ReflectionInternational Journal of the Economics of Business, Vol. 18, No. 2The (Paper)Work of Medicine: Understanding International Medical CostsJournal of Economic Perspectives, Vol. 25, No. 2A dynamic perspective on pharmaceutical competition, drug development and cost effectivenessHealth Policy, Vol. 100, No. 1Proactive R&D management and firm growth: A punctuated equilibrium modelResearch Policy, Vol. 40, No. 3The Contribution of the United States, Europe and Japan in Discovering New Drugs: 1982–2003Intellectual Property, Information Technology, Biomedical Research, and Marketing of Patented ProductsImpact of Profitability, R&D Intensity, and Cash Flow on R&D Expenditure in Pharmaceutical CompaniesSSRN Electronic JournalFactors Influencing Sales Revenue in the Multinational Pharmaceutical CompaniesSSRN Electronic JournalM&A of Generic Pharmaceutical Companies Increases ProductivitySSRN Electronic JournalApplying Data Envelopment Analysis and Multiple Objective Data Envelopment Analysis to Identify Successful Pharmaceutical Companies28 February 2011Pharmaceutical R&D Spending and Threats of Price Regulation26 November 2009 | Journal of Financial and Quantitative Analysis, Vol. 45, No. 1Pharmaceutical InnovationChapter 10 A Survey on the Economics of the U.S. Pharmaceutical Industry8 March 2015An exploratory study of FDA new drug review times, prescription drug user fee acts, and R&D spendingThe Quarterly Review of Economics and Finance, Vol. 49, No. 4Balancing Innovation and Access: Patent Challenges Tip the ScalesScience, Vol. 326, No. 5951Regulation and pricing of pharmaceuticals: Reference pricing or price cap regulation?European Economic Review, Vol. 53, No. 2On international cost-sharing of pharmaceutical R&D19 June 2008 | International Journal of Health Care Finance and Economics, Vol. 8, No. 4Patentes farmacêuticas e saúde pública: desafios à política brasileira de acesso ao tratamento anti-retroviralCadernos de Saúde Pública, Vol. 24, No. 7The Effect Of Regulation On Pharmaceutical Revenues: Experience In Nineteen Countries If the United States implemented price controls and negotiations similar to those in other developed countries, U.S. revenues would fall by as much as 20.3 percent.Neeraj Sood, Han de Vries, Italo Gutierrez, Darius N. Lakdawalla, and Dana P. Goldman16 December 2008 | Health Affairs, Vol. 27, No. Supplement 1U.S. Pharmaceutical Policy In A Global Marketplace Reducing copays tends to be a robust and welfare-improving policy, while imposing price controls risks high costs in the hope of a relatively modest benefit.Darius N. Lakdawalla, Dana P. Goldman, Pierre-Carl Michaud, Neeraj Sood, Robert Lempert, Ze Cong, Han de Vries, and Italo Gutierrez16 December 2008 | Health Affairs, Vol. 27, No. Supplement 1Price Controls And Global Pharmaceutical Progress A closer look at the analysis of Lakdawalla and colleagues.F.M. Scherer16 December 2008 | Health Affairs, Vol. 27, No. Supplement 1Timing New Drug Introductions: The Roles of Regulatory Rules and Firms' Complementary AssetsSSRN Electronic JournalThe Effect of Advertising on Pharmaceutical Innovation11 October 2007 | Review of Industrial Organization, Vol. 31, No. 3IMPORTATION AND INNOVATIONEconomics of Innovation and New Technology, Vol. 16, No. 6Endogenous innovations in the pharmaceutical industry12 May 2007 | Journal of Evolutionary Economics, Vol. 17, No. 4Pharmaceutical Strategy and Innovation: An Academics PerspectiveChemMedChem, Vol. 2, No. 6Uncertainty and choice: the challenges of pharmaceutical efficacy, safety, and cost1 January 2007 | Managerial and Decision Economics, Vol. 28, No. 4-5The cost of US pharmaceutical price regulation: a financial simulation model of R&D decisions1 January 2007 | Managerial and Decision Economics, Vol. 28, No. 4-5Determinants of drug prices and expenditures1 January 2007 | Managerial and Decision Economics, Vol. 28, No. 4-5A primer on the economics of re-importation of prescription drugs1 January 2007 | Managerial and Decision Economics, Vol. 28, No. 4-5New estimates of pharmaceutical research and development spending by US-based firms from 1984 to 20031 January 2007 | Managerial and Decision Economics, Vol. 28, No. 4-5Pharmaceutical Manufacturing Efficiency, Drug Prices, and Public Health: Examining the Causal Links30 December 2007 | Drug Information Journal, Vol. 41, No. 2Does Public Scientific Research Complement Private Investment in Research and Development in the Pharmaceutical Industry?The Journal of Law and Economics, Vol. 50, No. 1Pharmaceutical InnovationSSRN Electronic JournalTRIPS and the pharmaceutical industry: Prescription for profit?Critical Perspectives on Accounting, Vol. 17, No. 8Understanding Drug PricingCFA Institute Conference Proceedings Quarterly, Vol. 23, No. 1Setting the record straight in the reply by DiMasi, Hansen and GrabowskiJournal of Health Economics, Vol. 24, No. 5The Pharmaceutical Research Manufacturing Industry20 March 2013Drug Prices and Research and Development Investment Behavior in the Pharmaceutical IndustryThe Journal of Law and Economics, Vol. 48, No. 1Examining the link between price regulation and pharmaceutical R&D investment29 April 2004 | Health Economics, Vol. 14, No. 1Macro trends in pharmaceutical innovationNature Reviews Drug Discovery, Vol. 4, No. 1Pharmaceutical pricing, price controls, and their effects on pharmaceutical sales and research and development expenditures in the European UnionClinical Therapeutics, Vol. 26, No. 8A Note on Global Welfare in Pharmaceutical PatentingWorld Economy, Vol. 27, No. 7R&D Costs and Returns by Therapeutic Category30 December 2004 | Drug Information Journal, Vol. 38, No. 3Market power and the pharmaceutical industry in South AfricaEconomic Affairs, Vol. 24, No. 2Patents, Price Regulation and Innovation in the Pharmaceutical IndustrySSRN Electronic JournalA Note on Global Welfare in Pharmaceutical PatentingSSRN Electronic JournalAre the Economics of Pharmaceutical Research and Development Changing?PharmacoEconomics, Vol. 22, No. Supplement 2The Trips Agreement as an Alliance for Knowledge Production1 November 2005 | The Journal of World Intellectual Property, Vol. 6, No. 4The relationship between price regulation and pharmaceutical profit marginsApplied Economics Letters, Vol. 10, No. 8The Efficient Use Of Pharmaceuticals: Does Europe Have Any Lessons For A Medicare Drug Benefit?Adrian Towse17 August 2017 | Health Affairs, Vol. 22, No. 3The price of innovation: new estimates of drug development costsJournal of Health Economics, Vol. 22, No. 2Pharmaceuticals in U.S. Health Care: Determinants of Quantity and PriceJournal of Economic Perspectives, Vol. 16, No. 4Returns on Research and Development for 1990s New Drug IntroductionsPharmacoEconomics, Vol. 20, No. Supplement 3Perspectives On The Pharmaceutical IndustryUwe E. Reinhardt17 August 2017 | Health Affairs, Vol. 20, No. 5
Publication Year: 2001
Publication Date: 2001-09-01
Language: en
Type: article
Indexed In: ['crossref', 'pubmed']
Access and Citation
Cited By Count: 187
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot